? BIOINFORMATICS SHARED RESOURCE (BISR) The BISR is an essential shared resource that supports a wide range of studies with bioinformatics and computational biology needs, ranging from next generation sequencing (NGS) to data management in population science studies. Housed within the Department of BMI, the BISR's goal is to leverage a variety of informatics services, ranging from analysis of omics datasets to patient/participant-centered data instrumentation, access, and management tools and processes.
The Specific Aims of the BSR are to: 1) Provide state of the art bioinformatics and computational biology services; and 2) Provide OSUCCC investigators with services, expertise and access to technology platforms in support of heterogeneous and multi-dimensional biomedical data management requirements. Over the current grant cycle, Drs. Kevin Coombes (TT) and Lang Li (CB) assumed leadership of BISR, replacing Drs. Philip Payne and Jeffrey Parvin. During the current funding cycle, a Memorandum of Understanding (MOU) was established for the Department of Biomedical Informatics (BMI) and the OSUCCC to support 5 faculty at 10% per year for 3 years within BISR as they transition to grant funding, on a rolling basis, to provide non-chargeable, cancer focused bioinformatics work for OSUCCC membership and/or cancer focused researchers. Additional major changes for BISR include supporting the enhancement of the Genomics Shared Resource (GSR) to incorporate newly developed shared services with Nationwide Children's Hospital (NCH); and added capabilities to support studies involving data from single-cell sequencing, long-read (third generation) sequencing, metabolomics, and metagenomics. BISR has added five new faculty to support the areas of (1) computational optimization for drug sensitivity prediction (Cheng), (2) proteomics, and functional annotation of DNA non-coding regions (Zhang), (3) metabolomics and metagenomics (Mathe), (4) single-cell sequencing (Ma), and (5) long-read sequencing (Au). BISR supported Biospecimen Services Shared Resource (BSSR) projects (Total Cancer Care [TCC] and the Oncology Research Information Exchange Network [ORIEN]) by establishing a data warehouse of patient records with de-identified data. During the current funding cycle, the BISR supported 115 publications (25 > 10 impact factor), 134 users, and 32 NCI grants including 5 P01s, 2 P50s, 13 R01s, 3 R21s, 1 R50, 2 U01s, 1 U10, 1 UG1, involving members from all five programs. Over the next grant cycle, BISR will enhance services for ?integromics?, e.g., the integration of disparate source of both omics and clinical data. BISR will be a critical part of the Immune Monitoring and Discovery Platform (IMDP), an overarching approach for fostering interactions among shared resources for complex immuno-oncology projects. The annual budget of the BISR is $1,122,279, yet the CCSG request is $106,905. As such, the BISR leverages extensive institutional support and seeks only 9.5% support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090004
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Lehmann, Vicky; Nahata, Leena; Ferrante, Amanda C et al. (2018) Fertility-Related Perceptions and Impact on Romantic Relationships Among Adult Survivors of Childhood Cancer. J Adolesc Young Adult Oncol 7:409-414
Dix, David B; Seibel, Nita L; Chi, Yueh-Yun et al. (2018) Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol 36:1564-1570
Kohnken, Rebecca; Wen, Jing; Mundy-Bosse, Bethany et al. (2018) Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma. Blood 131:771-781
Londhe, Priya; Yu, Peter Y; Ijiri, Yuichi et al. (2018) Classical NF-?B Metabolically Reprograms Sarcoma Cells Through Regulation of Hexokinase 2. Front Oncol 8:104
Valenciaga, Anisley; Saji, Motoyasu; Yu, Lianbo et al. (2018) Transcriptional targeting of oncogene addiction in medullary thyroid cancer. JCI Insight 3:
Kiss, Daniel L; Baez, William D; Huebner, Kay et al. (2018) Loss of fragile histidine triad (Fhit) protein expression alters the translation of cancer-associated mRNAs. BMC Res Notes 11:178
Vasu, Sumithira; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv 2:1645-1650
Denton, Nicholas L; Chen, Chun-Yu; Hutzen, Brian et al. (2018) Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment. Mol Ther Oncolytics 11:62-74
Krasnick, Bradley A; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium. J Surg Oncol 117:363-371
Badawi, Mohamed; Kim, Jihye; Dauki, Anees et al. (2018) CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128. Oncotarget 9:26032-26045

Showing the most recent 10 out of 2602 publications